For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Study of Ocular Side Effects in Subjects with Glioblastoma
The main purpose of this study is to improve treatment of ocular (eye) side effects that result from depatuxizumab mafodotin (Depatux-M) use in subjects with glioblastoma (GBM).
In order to participate you must meet the following criteria:
- Have newly diagnosed glioblastoma (GBM) histologically proven, World Health Organization (WHO) grade IV GBM or WHO grade IV gliosarcoma.
- Demonstrate epidermal growth factor receptor (EGFR) amplification.
- Have recovered from the effects of surgery, postoperative infection, and other complications; has no significant post-operative hemorrhage.
You will be excluded from the study if any of the following criteria apply to you:
- Have been newly diagnosed with GBM and have received prior chemotherapy or radiotherapy for cancer of the head and neck region; have received prior treatment with Gliadel wafers or any other intratumoral or intracavitary treatment.
- Have hypersensitivity to any component of TMZ or dacarbazine.
- Have received anti-cancer therapy (including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any investigational therapy) within 5 years of Study Day 1.
This is a partial list of inclusion and exclusion criteria.